Innovations in Prostate Cancer Treatment: Antibody-Based Radioligand Therapy and Combinations Show Promise
/in Review/by MaxTransdermal Estradiol: A Cost-Saving, Quality-of-Life Boost for Prostate Cancer Therapy
/in Review/by MaxNavigating Treatment Options after Triplet Therapy Failure in Prostate Cancer: Should a Second ARPI Be Considered?
/in Review/by MaxMetastasis-Directed Therapy: A Paradigm Shift in Metastatic Prostate Cancer Treatment
/in Review/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Two-Pronged Drug Combination for Advanced Prostate Cancer: Fadraciclib Plus Ipatasertib (or Capivasertib) October 16, 2025
- Phase 2: Copper-Based PET Imaging Agent Surpasses Standard Tracer for Early Prostate Cancer Lesion Detection October 16, 2025
- Phase 2 Trial: Optimal PSA-Triggered Intermittent Therapy for mHSPC October 15, 2025
- Self-Assembled Nano-PROTAC to Improve Targeted Therapy in Castration-Resistant Prostate Cancer October 15, 2025